摘要
目的:基于网络药理学探讨藿朴夏苓汤治疗新型冠状病毒肺炎(COVID-19)的分子机制,为其临床治疗、实验室研究提供新思路。方法:通过TCMSP数据库获得藿朴夏苓汤的药物活性成分及作用靶点,利用GeneCards数据库检索COVID-19相关疾病靶点,将上述二者的共同靶点输入STRING数据库获取靶点蛋白互作网络关系,利用Cytoscape 3.7.2软件构建蛋白互作网络、"药物-成分-靶点-疾病"网络,并通过Cytoscape 3.7.2软件、R软件及相应程序包进行GO功能富集分析及KEGG通路富集分析。结果:筛选得到藿朴夏苓汤96个活性成分和697个作用靶点,其中与COVID-19共同作用靶点43个,GO功能富集分析得到1901个条目(P<0.05),KEGG富集分析得到146条相关信号通路(P<0.05),主要涉及IL-17信号通路、NF-κB信号通路等。结论:藿朴夏苓汤可能通过多靶点、多通路从炎症反应、免疫调节、细胞凋亡等方面进行干预,从而起到治疗COVID-19的作用。
Objective:To explore the molecular mechanism of Huopo xialing decoction for the treatment of novel coronavirus pneumonia(COVID-19)based on network pharmacology,so as to provide new ideas for its clinical treatment and laboratory research.Methods:The drug active ingredients and action targets of Huopo xialing decoction were screened by using the TCMSP database.The targets related COVID-19 were retrieved by using the GeneCards database.The common targets of the above two were input into the STRING database to obtain the protein-protein interaction PPI network relationship.Cytoscape3.7.2 software was used to construct PPI network and"drug-ingredient-target-disease"network.GO function enrichment analysis and KEGG pathway enrichment analysis were performed by Cytoscape3.7.2 software,R software and the corresponding program package.Results:96 active ingredients and 697 targets of Huopo xialing decoction were screened.And there were 43 targets related to COVID-19.1901 entries were obtained by GO function enrichment analysis(P<0.05),and 146 signaling pathways were obtained by KEGG enrichment analysis(P<0.05),which mainly involved the IL-17 signal pathway,NF-κB signal pathway and others.Conclusion:Huopo xialing decoction may treat COVID-19 by intervening inflammatory response,immune regulation and apoptosis through multiple targets and multiple pathways.
作者
谢铱子
纪树亮
钟彩婷
詹少锋
黄慧婷
刘小虹
XIE Yi-zi;JI Shu-liang;ZHONG Cai-ting;ZHAN Shao-feng;HUANG Hui-ting;LIU Xiao-hong(The First Clinical College,Guangzhou University of Chinese Medicine,Guangzhou 510405,China;First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,China)
出处
《中药材》
CAS
北大核心
2020年第5期1280-1290,共11页
Journal of Chinese Medicinal Materials
基金
国家自然科学基金面上项目(81973814)
刘小虹广东省名中医传承工作室建设项目(粤中医办函[2018]5号)
